Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Heart Rhythm O2 ; 5(5): 289-293, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38840769

RESUMO

Background: Cardiovascular implantable electronic device (CIED) infections are a common indication for device extraction. Early diagnosis and complete system removal are crucial to reduce morbidity and mortality. The lack of clear infectious symptoms makes the diagnosis of pocket infections challenging and may delay referral for extraction. Objective: We aimed to determine if inflammatory biomarkers can help diagnose CIED isolated pocket infection. Methods: We performed a retrospective analysis of all patients undergoing transvenous lead extraction for CIED infection at the University of California San Diego from 2012 to 2022 (N = 156). Patients were classified as systemic infection (n = 88) or isolated pocket infection (n = 68). Prospectively collected preoperative procalcitonin (PCT), C-reactive protein, and white blood cell count were compared between groups. Results: Pairwise comparisons revealed that the systemic infection group had a higher PCT than the control group (P < .001) and the pocket infection group (P = .009). However, there was no significant difference in PCT value between control subjects and isolated pocket infection subjects. Higher white blood cell count was only associated with systemic infection when compared with our control group (P = .018). Conclusion: In patients diagnosed with CIED infections requiring extraction, inflammatory biomarkers were not elevated in isolated pocket infection. Inflammatory markers are not predictive of the diagnosis of pocket infections, which ultimately requires a high level of clinical suspicion.

2.
Card Electrophysiol Clin ; 16(2): 143-147, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38749633

RESUMO

We present a complex case of cardiac implantable electronic device infection and extraction in the setting of bacteremia, large lead vegetation, and patent foramen ovale. Following a comprehensive preprocedural workup including transesophageal echocardiogram and computed tomography lead extraction protocol, in addition to the involvement of multiple subspecialties, an open chest approach to extraction was deemed a safer option for eradication of the patient's infection. Despite percutaneous techniques having evolved as the preferred extraction method during the last few decades, this case demonstrates the importance of a thorough evaluation at an experienced center to determine the need for open chest extraction.


Assuntos
Desfibriladores Implantáveis , Remoção de Dispositivo , Marca-Passo Artificial , Infecções Relacionadas à Prótese , Humanos , Remoção de Dispositivo/métodos , Desfibriladores Implantáveis/efeitos adversos , Infecções Relacionadas à Prótese/cirurgia , Infecções Relacionadas à Prótese/diagnóstico por imagem , Marca-Passo Artificial/efeitos adversos , Masculino , Ecocardiografia Transesofagiana , Tomografia Computadorizada por Raios X , Idoso , Forame Oval Patente/cirurgia , Forame Oval Patente/diagnóstico por imagem , Feminino , Pessoa de Meia-Idade
5.
ASAIO J ; 64(3): 323-327, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-28841580

RESUMO

Patients with Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) levels 1-2 who either have or are at risk for right ventricular failure face significant morbidity and mortality after continuous flow left ventricular assist device (CF-LVAD) implantation. Currently, the options for biventricular support are limited the Total Artificial Heart (TAH; CardioWest, Syncardia, Tuscon, AZ) or biventricular assist device (BiVAD), which uses bulky extracorporeal or implantable displacement pumps. We describe a successful series based on an innovative approach for biventricular support in consecutive INTERMACS levels 1-2 patients utilizing a HeartWare Ventricular Assist Device (HVAD; HeartWare, Framingham, MA) in a left ventricular (LV-HVAD) and a right atrial (RA-HVAD) configuration. From June 2014 through May 2016, 11 consecutive INTERMACS levels 1-2 patients with evidence of biventricular failure underwent implantation of a CF LVAD (10 LV-HVAD and 1 HeartMate II LVAD, Thoratec, Pleasanton, CA) and RA-HVAD pumps. A total of 4,314 BiVAD support days were accumulated in our case series. Seven patients have undergone orthotopic heart transplant, whereas 3 are ambulatory and are either waiting transplant or reconsideration for transplantation. There is one mortality in this case series, which was due to an intracranial bleed from supratherapeutic anticoagulation. Two other patients experienced hemorrhagic strokes, but without neurologic sequelae, whereas no patients have experienced ischemic strokes. There were two episodes of gastrointestinal bleeding. This is the largest series to date involving this approach with outcomes superior to those previously described in patients receiving biventricular support. We conclude this novel therapy is a viable alternative to current practices in the management of biventricular failure.


Assuntos
Procedimentos Cirúrgicos Cardiovasculares/métodos , Átrios do Coração/cirurgia , Ventrículos do Coração/cirurgia , Coração Auxiliar , Implantação de Prótese/métodos , Adulto , Feminino , Insuficiência Cardíaca/cirurgia , Transplante de Coração , Ventrículos do Coração/fisiopatologia , Coração Auxiliar/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/etiologia , Sistema de Registros , Estudos Retrospectivos , Resultado do Tratamento , Disfunção Ventricular Direita/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...